89 FR 190 pgs. 79950-79951 - Importer of Controlled Substances Application: Fresenius Kabi USA, LLC
Type: NOTICEVolume: 89Number: 190Pages: 79950 - 79951
Pages: 79950, 79951Docket number: [Docket No. DEA-1435]
FR document: [FR Doc. 2024-22450 Filed 9-30-24; 8:45 am]
Agency: Justice Department
Sub Agency: Drug Enforcement Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1435]
Importer of Controlled Substances Application: Fresenius Kabi USA, LLC
AGENCY:
Drug Enforcement Administration, Justice.
ACTION:
Notice of application.
SUMMARY:
Fresenius Kabi USA, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
DATES:
Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before October 31, 2024. Such persons may also file a written request for a hearing on the application on or before October 31, 2024.
ADDRESSES:
[top] The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short
SUPPLEMENTARY INFORMATION:
In accordance with 21 CFR 1301.34(a), this is notice that on August 12, 2024, Fresenius Kabi USA, LLC, 3159 Staley Road, Grand Island, New York 14072-2028, applied to be registered as an importer of the following basic class(es) of controlled substance(s):
Controlled substance | Drug code | Schedule |
---|---|---|
Remifentanil | 9739 | II |
The company plans to import the listed controlled substance(s) as bulk active pharmaceutical ingredient to manufacture Food and Drug Administration (FDA)-approved dosage forms. No other activity for this drug code is authorized for this registration.
Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of FDA-approved or non-approved finished dosage forms for commercial sale.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-22450 Filed 9-30-24; 8:45 am]
BILLING CODE P